Clinical updates, including trial initiations, enrollment status and data readouts and publications: Affimed, Akero, Ascentage, Ascletis, Astrazeneca, Atara, Biomarin, Biosig, Cara, Contrafect, Dare, Dynavax, Evgen, Inflarx, Kiniksa, Lilly, Merck, Nantpharma, Recordati, Remegen, Sagimet.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Affibody, Amylyx, Applied Therapeutics, Ardelyx, Atyr, Bayer, Beyondspring, Cardiff Oncology, Catalyst, Genentech, Glycomimetics, Humanigen, Immunic, Immunicum, Inventiva, Iveric, Kyowa Kirin, Lilly, Lundbeck, Momenta, Navidea, Oncimmune, Phathom, PTC, Roche, Sinovac, Solasia, Tarsus.

HONG KONG – Astellas Pharma Inc. reported positive results from phase III of its DOLOMITES study comparing the efficacy and safety of roxadustat to that of darbepoetin alfa in treating anemia in nondialysis-dependent, stage 3 to 5 chronic kidney disease (CKD) patients.

HONG KONG – Singapore-based Tychan Pte. Ltd. is starting a phase I trial for a novel monoclonal antibody (MAb) that specifically targets SARS-CoV-2, the coronavirus that causes COVID-19. The trial is expected to take only around six weeks to complete.

All the primary and secondary efficacy endpoints were met in Boulder, Colo.-based Brickell Biotech Inc.’s pivotal phase III study of the anticholinergic sofpironium bromide in treating primary axillary hyperhidrosis, which involves excessive sweating in the armpits that interferes with daily life and work.

HONG KONG – Japan’s Seikagaku Corp. is contemplating the next move for its ONO-5704/SI-613 (diclofenac etalhyaluronate), a treatment for arthritis that it is co-developing with fellow Japanese company Ono Pharmaceutical Co. Ltd.